NCT06429345

Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

Possible Role of Coenzyme Q10 in Prevention of Contrast Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Coronary Angiography With or Without Intervention.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.

Detailed description

Patients who fulfilled the inclusion criteria and agreed to participate in the study will be randomly divided into 2 groups using their computer generated random numbers that group a will receive the coenzyme Q10 in addition to the standard preventive measures and group b will receive only the standard preventive measures without the coenzyme Q10.

Conditions

• Contrast-induced Nephropathy

Interventions

Type	Name	Description
DRUG	Coenzyme Q10 100 Milligrams Oral Capsule	Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
DRUG	Placebo	placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.

Timeline

• Start date: 2024-06-15
• Primary completion: 2024-10-01
• Completion: 2024-11-01
• First posted: 2024-05-28
• Last updated: 2024-06-28

Locations

2 sites across 1 country: Egypt

Regulatory

• FDA-regulated drug study